This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) shed 8.04% to $9.15 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index falling 0.84% to 25,870.71 and Dow Jones Industrial Average falling 0.65% to 49,363.88.
This was the stock's fourth consecutive day of losses.
Corbus Pharmaceuticals Holdings Inc. closed 55.50% below its 52-week high of $20.56, which the company achieved on October 20th.
The stock underperformed when compared to some of its competitors Tuesday, as Vanda Pharmaceuticals Inc. (VNDA) fell 1.48% to $5.99, Fortress Biotech Inc. (FBIO) rose 2.02% to $2.53, and Viking Therapeutics Inc. (VKTX) fell 1.01% to $28.40.
Trading volume (324,136) eclipsed its 50-day average volume of 264,933.
Data source: Dow Jones Market Data, FactSet. Data compiled May 19, 2026.
This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-19-26 1719ET

CRBP

SBIO

IBBQ

LABU

Corbus Pharmaceuticals Holdings Inc. (CRBP) shares fell 8.04% to $9.15 on Tuesday, marking the fourth consecutive day of losses. The stock is now 55.50% below its 52-week high of $20.56. In comparison, competitors Vanda Pharmaceuticals Inc. and Fortress Biotech Inc. had mixed performances, with Vanda down 1.48% and Fortress up 2.02%. Overall, the NASDAQ Composite Index dropped 0.84%.

MarketWatch Automated

Corbus Pharma

ALPS Medical Breakthrough

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

NASDAQ Composite Index

Dow Jones Industrial Average

Vanda Pharma

Fortress Biotech

Viking Therap

Fortress Biotech Pref Share FBIOP 9.375 15/12/22

Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors